Phaseline

Companies › Eyestem Research

Eyestem Research: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tacrolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 1Retinal DiseaseDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06394232TacrolimusPhase 1Retinal DiseaseOphthalmologyDec 2030

Targets

FKBP1A (1)

Companies with the same targets

Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis Rapamycin Holdings AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.